title: Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis.
abstract: BACKGROUND
  Meropenem (MP), a new carbapenem antibiotic, has excellent antimicrobial activity against the enteric flora commonly encountered in acute appendicitis. Although similar to imipenem, it may have clinical advantages.
  
  
  METHODS
  We compared patients with advanced appendicitis (gangrenous or perforated) treated with 1,000 mg MP every eight hours with those given the combination of tobramycin 5 mg/kg/day at eight hour intervals and clindamycin 900 mg every eight hours. Both treatments were given intravenously. Patients were randomized to either group of the double-blind study.
  
  
  RESULTS
  Of 129 evaluable cases, 63 received MP and 66 received both tobramycin and clindamycin (T/C). The two groups were similar in age, sex, and severity of disease. The mean number of days of postoperative fever (MP = 3.1 +/- 1.7 SD compared to T/C = 4.4 +/- 2.2 SD, p < or = 0.01), days of antibiotic therapy (MP = 6.1 +/- 1.6 SD compared to T/C = 7.3 +/- 2.2 SD, p = 0.01), and therefore hospital stay (MP = 8.0 +/- 3.5 SD compared to T/C = 9.4 +/- 2.6 SD, p < 0.01) were significantly better for patients treated with MP. No difference was found between the numbers of failures in each group (MP = 5 compared to T/C = 6).
  
  
  CONCLUSIONS
  This study demonstrates a small but significant reduction (approximately one day) in post-operative fever, duration of antibiotic treatment, and hospital stay for patients treated with MP compared to those treated with T/C.
authors.affiliation: Department of Surgery, School of Pharmacy, University of Southern California, Los Angeles, USA.
authors.forename: T V
authors.initials: TV
authors.lastname: Berne
authors.forename: A E
authors.initials: AE
authors.lastname: Yellin
authors.forename: M D
authors.initials: MD
authors.lastname: Appleman
authors.forename: P N
authors.initials: PN
authors.lastname: Heseltine
authors.forename: M A
authors.initials: MA
authors.lastname: Gill
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001064:Appendicitis / Q000188:drug therapy*; D002981:Clindamycin / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007416:Intestinal Perforation / Q000188:drug therapy; D007902:Length of Stay; D008297:Male; D000077731:Meropenem; D012422:Rupture, Spontaneous; D013845:Thienamycins / Q000627:therapeutic use*; D013997:Time Factors; D014031:Tobramycin / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D013845:Thienamycins; D002981:Clindamycin; D000077731:Meropenem; D014031:Tobramycin